Abstract
Inflammatory bowel disease (IBD) encompasses a group of chronic inflammatory disorders of the gastrointestinal tract, including Crohn's disease and ulcerative colitis. The management of IBD often involves the use of pharmacological agents aimed at controlling inflammation, modulating the immune response, and promoting mucosal healing. This article reviews the role of pharmacological agents in treating IBD, including aminosalicylates, corticosteroids, immunomodulators, biologic therapies, and small molecules. We also explore the mechanisms of action, clinical efficacy, and potential side effects of these agents, as well as recent advances in the development of targeted therapies for IBD.
All articles published in the American Journal of Pharmacy and Pharmacology are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows others to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given to the original author(s) and source, a link to the license must be provided, and any changes made must be indicated.
By submitting their work, authors agree to these licensing terms and retain copyright of their articles.